lupus erythematosus, systemic

Classification criteria: time for a rethink?
Duncan Porter, Neil Basu, Stefan Siebert

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1264-1266; DOI: 10.1136/annrheumdis-2020-217769
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1382-1383; DOI: 10.1136/annrheumdis-2020-217717
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19
Maximilian F Konig, Alfred HJ Kim, Marc H Scheetz, Elizabeth R Graef, Jean W Liew, Julia Simard, Pedro M Machado, Milena Gianfrancesco, Jinoos Yazdany, Daman Langguth, Philip C Robinson

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1386-1388; DOI: 10.1136/annrheumdis-2020-217690
Rheumatic disease and COVID-19
Jean W Liew, Elizabeth R Graef

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-217674; DOI: 10.1136/annrheumdis-2020-217674
High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern
Murat İnanç, Bahar Artim-Esen, Reyhan Diz-Küçükkaya

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218345; DOI: 10.1136/annrheumdis-2020-218345
Implications of SARS-CoV-2 infection for patients with rheumatic disease
Changsong Lin, Ziyu Wang, Jie Li, Xinyi Xia, Yun Liu, Qianghu Wang

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218050; DOI: 10.1136/annrheumdis-2020-218050
Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic
Seow Lin Chuah, Cheng Lay Teh, Sharifah Aishah Wan Mohd Akbar, Yaw Kiet Cheong, Benjamin Sachdev Manjit Singh

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218475; DOI: 10.1136/annrheumdis-2020-218475
Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus
Yasushi Kondo, Yuko Kaneko, Tatsuhiro Oshige, Hiroyuki Fukui, Shuntaro Saito, Mikio Okayama, Hirofumi Kamata, Makoto Ishii, Naoki Hasegawa, Koichi Fukunaga, Tsutomu Takeuchi

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218157; DOI: 10.1136/annrheumdis-2020-218157
Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial–comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al
Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G Tektonidou

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218444; DOI: 10.1136/annrheumdis-2020-218444
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al
Alessandra Bettiol, Francesca Pregnolato, Savino Sciascia, Giacomo Emmi, Domenico Prisco, Pier Luigi Meroni

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218377; DOI: 10.1136/annrheumdis-2020-218377

Main menu

lupus erythematosus, systemic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

lupus erythematosus, systemic

Pages